LGVN
Longeveron Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-49/100
Last price
2.35
▼ 0.16 (6.37%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
2.51
Day high
2.50
Day low
2.34
Volume
83.59K
Market cap
$7.49M
P/E (TTM)
—
52W range
2.30 – 12.30
Trailing performance
Returnvs SPY
1W
-13.60%
-15.6%
1M
-65.49%
-66.6%
3M
-63.45%
-68.0%
6M
-79.74%
-97.9%
YTD
-53.56%
-67.8%
1Y
-70.18%
-86.6%
3Y
-99.00%
-181.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on LGVN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+6.58M
Net buying
Buy transactions
88
6.85M shares
Sell transactions
11
269.49K shares
Net transactions
+99
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
471.76K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 19, 26 | CANN LEAH RUSH Director |
STOCK | 36.00K | $0 | Direct |
| Aug 19, 26 | ASCHEIM DEBORAH Director |
STOCK | 36.00K | $0 | Direct |
| Aug 19, 26 | HARE JOSHUA M Officer, Director and Beneficial Owner |
STOCK | 286.00K | $0 | Direct |
| Aug 19, 26 | SOFFER ROCK J Director |
STOCK | 36.00K | $0 | Direct |
| Aug 19, 26 | LEHR PAUL T General Counsel |
STOCK | 286.00K | $0 | Direct |
| Aug 19, 26 | UNGARO URSULA Director |
STOCK | 36.00K | $0 | Direct |
| Aug 19, 26 | AGAFONOVA NATALIYA Officer |
STOCK | 286.00K | $0 | Direct |
| Aug 19, 26 | DESAI ARJUN JJ Director |
STOCK | 36.00K | $0 | Direct |
| Aug 19, 26 | HAJJAR ROGER JOSEPH Director |
STOCK | 36.00K | $0 | Direct |
| Aug 19, 26 | BLASS DEVIN Chief Technology Officer |
STOCK | 286.00K | $0 | Direct |
| Aug 19, 26 | PALETTA GEORGE A JR. Director |
STOCK | 36.00K | $0 | Direct |
| May 1, 26 | WILLARD STEPHEN H Chief Executive Officer |
STOCK | 500.00K | $0 | Direct |
| May 1, 26 | LEHR PAUL T General Counsel |
STOCK | 250.00K | $0 | Direct |
| May 1, 26 | AGAFONOVA NATALIYA Officer |
STOCK | 250.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AGAFONOVA NATALIYA |
Officer | 716.91K | Stock Award(Grant) |
BLASS DEVIN |
Chief Technology Officer | 711.74K | Stock Award(Grant) |
HARE JOSHUA M |
Officer, Director and Beneficial Owner | 1.61M | Stock Award(Grant) |
HASHAD MOHAMED WA'EL AHMED |
Chief Executive Officer | 420.90K | Stock Award(Grant) |
LEHR PAUL T |
General Counsel | 861.42K | Stock Award(Grant) |
LOCKLEAR LISA |
Chief Financial Officer | 465.69K | Stock Award(Grant) |
POWELL JAMES NATHANIEL |
Chief Executive Officer | 130.45K | Stock Award(Grant) |
SOFFER ROCK J |
Director | 262.03K | Stock Award(Grant) |
UNGARO URSULA |
Director | 77.00K | Stock Award(Grant) |
WILLARD STEPHEN H |
Chief Executive Officer | 789.73K | Stock Award(Grant) |
Fundamentals
Market cap$7.49M
Enterprise value$-2.00M
Revenue (TTM)$1.19M
Gross profit$828.00K
EBITDA$-22.44M
Net income$-23.47M
EPS (TTM)$-9.90
Free cash flow$-11.60M
Total cash$10.08M
Total debt$581.00K
Book value / share$3.28
Shares outstanding3.04M
Float2.38M
Short % of float7.27%
Dividend yield0.00%
Beta (5Y)-0.20
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.54
PEG ratio—
Price / sales—
Price / book0.72
EV / revenue-1.69
EV / EBITDA0.09
Gross margin69.76%
Operating margin-2150.17%
Profit margin0.00%
Return on equity-203.61%
Return on assets-90.95%
Debt / equity5.59
Current ratio2.63
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.20M | $2.39M | $709.00K | $1.22M | — | -49.9% |
| Operating revenue | $1.20M | $2.39M | $709.00K | $1.22M | — | -49.9% |
| Cost of revenue | $396.00K | $508.00K | $488.00K | $725.00K | — | -22.0% |
| Gross profit | $803.00K | $1.88M | $221.00K | $497.00K | — | -57.4% |
| Research & development | $12.04M | $8.14M | $9.07M | $9.37M | — | +48.0% |
| Selling, general & admin | $12.05M | $10.27M | $12.18M | $9.17M | — | +17.3% |
| Total operating expense | $24.09M | $18.41M | $21.25M | $18.54M | — | +30.9% |
| Operating income | -$23.29M | -$16.52M | -$21.03M | -$18.04M | — | -40.9% |
| Net interest income | — | — | — | $0 | -$4.00K | — |
| Pre-tax income | -$22.70M | -$15.97M | -$21.41M | -$18.84M | — | -42.1% |
| Net income | -$22.70M | -$15.97M | -$21.41M | -$18.84M | — | -42.1% |
| Net income to common | -$22.70M | -$24.62M | -$22.21M | -$18.84M | — | +7.8% |
| Basic EPS | -1.29 | -2.62 | -10.22 | -9.00 | — | +50.8% |
| Diluted EPS | -1.29 | -2.62 | -10.22 | -9.00 | — | +50.8% |
| EBIT | -$23.29M | -$16.52M | -$21.03M | -$18.04M | — | -40.9% |
| EBITDA | -$22.06M | -$15.56M | -$20.08M | -$17.15M | — | -41.7% |
| Basic shares | 17.58M | 9.41M | 2.17M | 2.10M | — | +86.8% |
| Diluted shares | 17.58M | 9.41M | 2.17M | 2.10M | — | +86.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.66M | $19.23M | $4.95M | $10.50M | -75.8% |
| Cash & short-term investments | $4.66M | $19.23M | $5.36M | $19.66M | -75.8% |
| Accounts receivable | $104.00K | $25.00K | $15.00K | $0 | +316.0% |
| Total current assets | $5.45M | $19.62M | $5.85M | $20.28M | -72.2% |
| Property, plant & equipment | $2.35M | $3.33M | $3.75M | $4.48M | -29.5% |
| Goodwill & intangibles | $2.29M | $2.40M | $2.29M | $2.41M | -4.8% |
| Total assets | $10.26M | $25.56M | $12.08M | $27.41M | -59.9% |
| Total current liabilities | $4.09M | $2.58M | $3.89M | $4.87M | +58.3% |
| Total debt | $824.00K | $1.45M | $2.04M | $2.60M | -43.1% |
| Total liabilities | $4.59M | $3.67M | $5.34M | $6.91M | +24.9% |
| Retained earnings | -$132.31M | -$109.61M | -$84.98M | -$62.77M | -20.7% |
| Shareholder equity | $5.67M | $21.89M | $6.74M | $20.50M | -74.1% |
| Working capital | $1.36M | $17.04M | $1.96M | $15.41M | -92.0% |
| Net tangible assets | $3.39M | $19.49M | $4.45M | $18.09M | -82.6% |
| Shares issued | 22.93M | 14.89M | 2.51M | 2.10M | +54.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$22.70M | -$15.97M | -$21.41M | -$18.84M | -42.1% |
| Depreciation & amortisation | $1.23M | $958.00K | $946.00K | $893.00K | +28.0% |
| Stock-based compensation | $1.68M | $2.33M | $2.03M | $2.17M | -28.0% |
| Change in working capital | $1.06M | -$1.24M | $321.00K | $238.00K | +185.3% |
| Operating cash flow | -$18.64M | -$13.87M | -$19.00M | -$13.97M | -34.4% |
| Capital expenditure | -$595.00K | -$992.00K | -$694.00K | -$856.00K | +40.0% |
| Investing cash flow | -$595.00K | -$640.00K | $8.19M | -$677.00K | +7.0% |
| Financing cash flow | $4.67M | $28.79M | $5.26M | -$509.00K | -83.8% |
| Free cash flow | -$19.24M | -$14.86M | -$19.70M | -$14.82M | -29.5% |
| End cash position | $4.66M | $19.23M | $4.95M | $10.50M | -75.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $287.00K | $398.00K | $365.00K | $137.00K | $316.00K | — | -27.9% |
| Operating revenue | $287.00K | $398.00K | $365.00K | $137.00K | $316.00K | — | -27.9% |
| Cost of revenue | $105.00K | $134.00K | $108.00K | $12.00K | $170.00K | — | -21.6% |
| Gross profit | $182.00K | $264.00K | $257.00K | $125.00K | $146.00K | — | -31.1% |
| Research & development | $3.19M | $2.32M | $2.72M | $3.85M | $2.95M | — | +37.7% |
| Selling, general & admin | $3.16M | $2.72M | $2.94M | $3.58M | $2.59M | — | +16.1% |
| Total operating expense | $6.35M | $5.04M | $5.66M | $7.43M | $5.54M | — | +26.1% |
| Operating income | -$6.17M | -$4.78M | -$5.40M | -$7.31M | -$5.40M | — | -29.2% |
| Pre-tax income | -$6.07M | -$4.74M | -$5.44M | -$7.22M | -$5.03M | — | -28.2% |
| Net income | -$6.07M | -$4.74M | -$5.44M | -$7.22M | -$5.03M | — | -28.2% |
| Net income to common | -$6.07M | -$4.74M | -$5.44M | -$7.22M | -$5.03M | — | -28.2% |
| Basic EPS | -0.19 | -0.19 | — | -0.39 | -0.33 | -0.34 | 0.0% |
| Diluted EPS | -0.19 | -0.19 | — | -0.39 | -0.33 | -0.34 | 0.0% |
| EBIT | -$6.17M | -$4.78M | -$5.40M | -$7.31M | -$5.40M | — | -29.2% |
| EBITDA | -$5.95M | -$4.52M | -$5.12M | -$7.05M | -$5.13M | — | -31.5% |
| Basic shares | 31.38M | 24.79M | — | 18.37M | 15.01M | 14.95M | +26.6% |
| Diluted shares | 31.38M | 24.79M | — | 18.37M | 15.01M | 14.95M | +26.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.08M | $15.76M | $4.66M | $9.24M | $10.33M | -36.1% |
| Cash & short-term investments | $10.08M | $15.76M | $4.66M | $9.24M | $10.33M | -36.1% |
| Accounts receivable | $65.00K | $68.00K | $104.00K | $52.00K | $31.00K | -4.4% |
| Total current assets | $11.32M | $16.86M | $5.45M | $10.34M | $11.27M | -32.8% |
| Property, plant & equipment | $1.95M | $2.10M | $2.35M | $2.73M | $2.96M | -7.1% |
| Goodwill & intangibles | $2.20M | $2.24M | $2.29M | $2.31M | $2.32M | -1.6% |
| Total assets | $15.49M | $21.21M | $10.26M | $15.56M | $16.75M | -27.0% |
| Total current liabilities | $4.31M | $4.34M | $4.09M | $4.94M | $3.28M | -0.9% |
| Total debt | $581.00K | $748.00K | $824.00K | $983.00K | $1.14M | -22.3% |
| Total liabilities | $5.08M | $5.18M | $4.59M | $5.59M | $4.09M | -1.9% |
| Retained earnings | -$143.12M | -$137.05M | -$132.31M | -$126.87M | -$119.65M | -4.4% |
| Shareholder equity | $10.40M | $16.03M | $5.67M | $9.97M | $12.66M | -35.1% |
| Working capital | $7.02M | $12.51M | $1.36M | $5.40M | $7.99M | -43.9% |
| Net tangible assets | $8.20M | $13.79M | $3.39M | $7.66M | $10.34M | -40.5% |
| Shares issued | 31.72M | 30.78M | 22.93M | 21.06M | 15.11M | +3.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$6.07M | -$4.74M | -$5.44M | -$7.22M | -$5.03M | -28.2% |
| Depreciation & amortisation | $221.00K | $252.00K | $278.00K | $264.00K | $263.00K | -12.3% |
| Stock-based compensation | $373.00K | $379.00K | $376.00K | $448.00K | $513.00K | -1.6% |
| Change in working capital | -$174.00K | -$265.00K | -$603.00K | $1.45M | $655.00K | +34.3% |
| Operating cash flow | -$5.65M | -$4.37M | -$5.30M | -$5.05M | -$3.60M | -29.4% |
| Capital expenditure | -$103.00K | -$20.00K | -$64.00K | -$118.00K | -$263.00K | -415.0% |
| Investing cash flow | -$103.00K | -$20.00K | -$64.00K | -$118.00K | -$263.00K | -415.0% |
| Financing cash flow | $75.00K | $15.49M | $777.00K | $4.08M | -$133.00K | -99.5% |
| Free cash flow | -$5.76M | -$4.39M | -$5.36M | -$5.17M | -$3.86M | -31.1% |
| End cash position | $10.08M | $15.76M | $4.66M | $9.24M | $10.33M | -36.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.90 | -1.90 | 0.0% |
| Mar 2026 | -1.73 | -1.90 | -10.1% |
| Dec 2025 | -3.67 | -2.20 | +40.0% |
| Sep 2025 | -2.57 | -3.90 | -51.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.93 | 3 | $509.00K | +271.5% |
| Next quarter | -1.77 | 3 | $546.67K | +49.8% |
| Current year | -7.63 | 3 | $1.75M | +46.2% |
| Next year | -4.93 | 3 | $8.70M | +396.5% |
Analyst targets & ownership
Mean target$61.25
High target$80.00
Low target$42.50
Implied upside2506.38%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 1
Hold1
Sell / Strong sell0 / 0
Held by insiders14.80%
Held by institutions22.61%
Institutions holding39
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.64
-10.95% from price
SMA 20
3.89
-39.57% from price
SMA 50
5.89
-60.07% from price
SMA 100
6.52
-63.94% from price
SMA 200
6.98
-66.32% from price
EMA 12
3.00
-21.63% from price
EMA 26
4.10
-42.72% from price
EMA 50
5.18
-54.60% from price
RSI (14)
24.7
Oversold
MACD (12,26,9)
-1.10
Hist -0.02
ATR (14)
0.52
22.22% of price
Realised vol 30D
270.4%
Annualised
Bollinger upper
7.76
20, 2σ
Bollinger lower
0.01
20, 2σ
50 / 200 cross
Death
5.89 vs 6.98
Trend bias
Below 200
-66.32%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.69
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
270.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-79.7%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
0.52
22.22% of price
Beta (reported)
-0.20
5Y monthly, from filing
Short interest
Shares short
213.78K
Prior 169.99K
Change vs prior
+25.8%
Shorts adding
% of float
7.27%
Normal
% of shares out
6.71%
Against total outstanding
Days to cover
2.9
Liquid
Float
2.38M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 11, 26 | Maxim Group | DOWNGRADE | Buy | Hold |
| May 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 25 | Roth Capital | MAINTAINED | Buy | Buy |
| Mar 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 3, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 5, 24 | Roth MKM | INITIATED | — | Buy |
| Nov 25, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 4, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 4, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 27, 24 | Maxim Group | MAINTAINED | Buy | Buy |
| Aug 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 31, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:10
Split dateAug 27, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-23
Corporate Changes & Voting Matters
8-K · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-08-24
Corporate Changes & Voting Matters
8-K · 2026-08-19
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-14
Offering Registrations
S-8 · 2026-07-10
Headlines
Longeveron to Participate in Three Longevity/Aging Investment Conferences
GlobeNewswire · 7d ago
Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?
Insider Monkey · 14d ago
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
BioPharma Dive · 19d ago
Top Midday Decliners
MT Newswires · 20d ago
LGVN Posts Disappointing Trial Results
Zacks Small Cap Research · 20d ago
Longeveron Shares Halted After Heart Therapy Trial Misses Primary Endpoint
MT Newswires · 20d ago
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
GlobeNewswire · 20d ago
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.